Omnibus bill recommends GAVI receive US$ 100 million, an increase of US$ 10.2 million on FY2011

Congress

Geneva, 21 December 2011 - The GAVI Alliance expresses its deep appreciation for an increase in funding secured in the Fiscal Year 2012 omnibus spending bill passed by the US Congress on 17 December. 

The omnibus bill recommends that GAVI receive US$ 100 million, an increase of US$10.2 million over the US$ 89.8 million appropriated in FY2011.

“Working with our partners, including USAID, we aim to immunise a quarter of a billion children by 2015,” said Seth Berkley, CEO of the GAVI Alliance. 

“We are grateful, that despite significant fiscal constraints, Congress has approved funding that will allow us to continue this important work and build on the measurable results we’ve achieved over more than a decade.”

Bipartisan support for global health

This strong backing by the United States is vital to ensure the world’s poorest people have access to life-saving vaccines

Seth Berkley MD, GAVI CEO

“We appreciate the bipartisan support for global health that is demonstrated by this action. This strong backing by the United States is vital to ensure the world’s poorest people have access to life-saving vaccines and a healthier, more prosperous future for themselves and their children.”

The GAVI Alliance is a public-private global health partnership committed to saving children’s lives and protecting people’s health by increasing access to immunisation in poor countries.

Over 5m deaths prevented

The Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society organisations, the Bill & Melinda Gates Foundation and other private philanthropists. 

In its first decade, the GAVI Alliance has prevented more than five million deaths by supporting immunisation. With full funding, GAVI can prevent another four million future deaths by 2015.

Subscribe to our newsletter